Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent: Experimental studies in pigs
Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent: Experimental studies in pigs
复制标题
DOI：
10.1016/s0002-8703(96)90002-2
复制
发表时间：
1996-11-01
影响因子：
4.8
通讯作者：
Sahn, DJ
中科院分区：
文献类型：
--
作者：
Grauer, SE;Pantely, GA;Sahn, DJ
能够提供可靠的静脉注射后心肌混浊的回声造影剂的开发是声学造影术临床应用的重要进展。在这项研究中，一种新的脂质-氟碳回声造影剂气雾体MRX 115(ImaRx制药公司，亚利桑那州图森市)的血流动力学效应和超声心动图特征。在6只麻醉呼吸的猪身上进行了研究。静脉注射这种新药物，剂量在0.0005-0.01ml/kg之间，可产生明显的可测量和可见的心肌混浊，而对心率、全身压、氧分压和左心室收缩功能没有任何影响。然而，最大的两个剂量(0.005和0.01ml/kg)导致平均肺动脉压轻度可逆升高，分别为12和16 mm Hg。在四只动物中，在冠状动脉闭塞前和闭塞期间获取心外膜图像。冠脉闭塞期间静脉注射造影剂可显示低灌注心肌节段。这一能力可能会进一步扩大声学造影的用途。
The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is an important advancement for the clinical application of contrast echocardiography. In this study, the hemodynamic effects and echocardiographic characteristics of a new lipid-fluorocarbon echo contrast agent, Aerosomes MRX 115 (ImaRx Pharmaceutical Corp., Tucson, Ariz.) were studied in six anesthetized ventilated pigs. Intravenous injection of this new agent in doses ranging from 0.0005 to 0.01 ml/kg produced significant measurable and visible myocardial opacification without any effect on heart rate, systemic pressure, partial pressure of oxygen, or left ventricular systolic function. The two largest doses (0.005 and 0.01 ml/kg), however, resulted in mild reversible increases in mean pulmonary artery pressure of 12 and 16 mm Hg, respectively. In four animals, epicardial images were obtained before and during coronary artery occlusion. Intravenous contrast injection during coronary occlusion permitted delineation of the hypoperfused myocardial segment. This capability may further expand the utility of contrast echocardiography.